Skip to main content

Table 2 Main outcomes

From: A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)

 

n (%) or median (range)

Days from operation to administration, day

54 (31–70)

Completion rate, %

25 (54.3%)

Completion rate without recurrence, %

25 (62.5%)

Reson of cessation (n = 21)

 Recurrence

6 (28.6%)

 Adverse event

13 (61.9%)

 Gastrointestinal

8

 Myelosuppression

2

 Stomatitis

1

 Cholangitis

1

 Chest pain

1

 Others

2 (9.5%)

 Traffic accident

1

 House-moving

1

 Relative dose intensity, %

62.9 (0.7–100)